Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 07 Aug 2025
Machine learning uncovers gut microbiome biomarkers linked to purine metabolism, enhancing diagnostic strategies for gout and hyperuricemia.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
Francis Collins reveals that he was diagnosed with "aggressive" prostate cancer.
2.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
3.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
4.
Safe and acceptable telehealth suicide prevention program.
5.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
1.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
2.
Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration
3.
A Revolutionary Guide to Calculating Absolute Neutrophil Counts
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge